Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

IMCD rises after strong half-year numbers — revenue, EBITA and free cash flow beat expectations

IMCD shares climbed 9.1% to €96.58 after results for H1 2026 were released. Operating EBITA for Q2 was €155.2m (consensus €146.0m) and organic revenue growth was 7.5% (consensus 5.0%). For the half-year, currency-adjusted EBITA rose to €285m (+8%), revenue reached €2,638m (+11% after exchange rate adjustments) and free cash flow increased 28% to €222m. CEO Marcus Jordan described the period positively and expressed confidence in further earnings growth; analyst updates, such as an upgrade by UBS, supported the rally. » More on de.investing.com
IMCD rises after UBS upgrade and price-target increase

UBS upgraded IMCD from “Neutral” to “Buy” and raised its price target from €85 to €100, after which the stock gained more than 5%. The bank sees a feasible path to organic EPS growth of 6–7%, supported by rising oil and chemical prices and ongoing supply-chain disruptions, which could add roughly 2% growth in 2026–27. UBS expects a slow volume recovery and a turnaround in revenue growth in Q2 2026, cites a bullish target of €140 and a negative scenario of €50. IMCD is currently trading at around 11x EV/EBITA for 2027; risks include cyclical industrial demand, regulatory and health-related issues, and fluctuations in product costs. » More on de.investing.com
IMCD exceeds Q1 EBITA thanks to growth in Asia-Pacific

IMCD reported an EBITA of €129.8 million for the first quarter of 2026, 9% below the prior year but 5% above the consensus estimate of €123.7 million. Organic sales fell 0.8%, while the Asia‑Pacific region grew by 3.5%; EMEA and the Americas saw declines. Gross and EBITA margins fell by 116 and 101 basis points respectively, though the EBITA margin of 10.2% was slightly above expectations. Free cash flow rose 19% to €121 million; leverage remained at 2.8 times EBITDA. IMCD does not provide guidance for 2026 but expects price increases, greater supply‑chain uncertainty and pressure on suppliers, and says it is well positioned. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, IMCD has already paid €1.81 in dividends. The last payout was in May.

Financials

In the last quarter, IMCD had revenue of €2.64B and net profit of €142.34M

(EUR)	June 2026	YoY
Revenue	2.64B	-
Gross profit	279.91M	-
Net profit	142.34M	-
EBITDA	306.45M	-

Fundamentals

Metric	Value
Market capitalization	€6.07B
Number of shares	59.04M
52-week high/low	€105.55 - €68.14
Dividend yield	1.77%
Dividends TTM	€1.81
Beta	0.98
P/E ratio	26.35
PEG ratio	-1.77
P/B ratio	2.86
P/S ratio	1.23

Company profile

IMCD N.V. distributes, markets, and sells specialty chemicals and ingredients in the Netherlands, rest of Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific. The company offers enzymes, surfactants, biocides, chelates, rheology modifiers, solubilisers, silicones, solvents, and functional additives; active pharmaceutical, agrochemicals, biopharma, excipients and formulation, nutraceuticals, and regulated synthesis; actives, UV sunscreens, rheology modifiers, thickeners, emulsifiers, emollients, elastomers, humectants, waxes, film formers, functional powders, hair styling polymers, hair conditioners, solvents, solubilizers, pigments, pearls, colorants, opacifiers, pearlisers, preservatives, antioxidants, additives, fragrances, and essential oils; and resins and binders, additives, functional fillers, and specialty solvents. It also provides taste, texture, nutrition, and function; base oil, fuel addictive, lubricants addictive, lubricants finished fluids, solvents, degreasers and fuel, compounds, and upstream, midstream and downstream oil, gas and energy; bio-based chemicals, catalysts, intermediates, monomers, organic building blocks, processing aids, reactive diluents, solvents, and surfactants. IMCD N.V. was founded in 1995 and is headquartered in Rotterdam, the Netherlands.